Based on data from the PatSnap Synapse database, we recently published Global Innovative Drug Report, which offers a comprehensive overview of the latest advancements in the pharmaceutical industry and analysis of each selected drug, examining their snapshot, R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors. The report consists of four parts:1.First Approved Drugs in July; 2. New Drug Analysis; 3. Global Drugs under Expedited Review Pathway in July; 4. Analysis of Selected ERP Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
By clicking “Accept Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and improve user experiences.
×
Manage Cookies
Cookies and similar technologies collect certain information about how you’re using our website. Some of them are essential, and without them you wouldn’t be able to use Canva. But others are optional, and you get to choose whether we use them or not.
Essential Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Performance Cookies
These cookies help us analyze how many people are using Synapse, where they come from and how they're using it. If you opt out of these cookies, we can’t get feedback to make Synapse better for you and all our users.